CLINICAL TRIALS PROFILE FOR INVERSINE

All Clinical Trials for INVERSINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00262470 ↗	Treatment of Orthostatic Intolerance	Active, not recruiting	National Institutes of Health (NIH)	Phase 1/Phase 2	1997-04-01	This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.
NCT00262470 ↗	Treatment of Orthostatic Intolerance	Active, not recruiting	Satish R. Raj	Phase 1/Phase 2	1997-04-01	This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.
NCT00319319 ↗	Nicotinic Receptor Augmentation of SSRI Antidepressants	Completed	Donaghue Medical Research Foundation	Phase 2	2003-01-01	The purpose of this study is to determine whether the nicotinic receptor antagonist mecamylamine hydrochloride (Inversine) can augment SSRI-refractory major depression symptoms, quality of life and cigarette smoking outcomes. A total of n=60 SSRI-refractory patients who are on stable doses of an SSRI are being recruited into this 8-week double-blind, randomized, placebo-controlled trial.
NCT00319319 ↗	Nicotinic Receptor Augmentation of SSRI Antidepressants	Completed	Yale University	Phase 2	2003-01-01	The purpose of this study is to determine whether the nicotinic receptor antagonist mecamylamine hydrochloride (Inversine) can augment SSRI-refractory major depression symptoms, quality of life and cigarette smoking outcomes. A total of n=60 SSRI-refractory patients who are on stable doses of an SSRI are being recruited into this 8-week double-blind, randomized, placebo-controlled trial.
NCT00455650 ↗	Study of the Effects of Mecamylamine and Varenicline in Schizophrenia	Completed	National Alliance for Research on Schizophrenia and Depression	N/A	2007-03-01	We are conducting this study to find out if blocking or partially stimulating the effects of nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug found in tobacco products. Our subjects will be people with and without mental illness (schizophrenia), smokers and non-smokers. We will use a medication called mecamylamine (Inversine) to block the effects of nicotine on the brains of our subjects. We will also use a medication called varenicline (Chantix) to partially increase the effects of nicotine on the brains of our subjects. This study also uses a placebo, a pill that does not have any active ingredients but looks exactly like the mecamylamine and varenicline pills. We will compare the effects of giving mecamylamine or placebo to people who have schizophrenia and people who do not have schizophrenia. We know that people with schizophrenia smoke heavily and find it harder to stop smoking than most other people do. Studies have shown that people with schizophrenia may smoke more because nicotine helps their concentration and memory. We are interested in helping people with schizophrenia smoke less. Mecamylamine blocks the parts of the brain that react to nicotine and varenicline partially stimulates and partially blocks the parts of the brain that react to nicotine. Both medications may decrease the effects that smoking has on the body.
NCT00455650 ↗	Study of the Effects of Mecamylamine and Varenicline in Schizophrenia	Completed	The Bowman Family Foundation	N/A	2007-03-01	We are conducting this study to find out if blocking or partially stimulating the effects of nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug found in tobacco products. Our subjects will be people with and without mental illness (schizophrenia), smokers and non-smokers. We will use a medication called mecamylamine (Inversine) to block the effects of nicotine on the brains of our subjects. We will also use a medication called varenicline (Chantix) to partially increase the effects of nicotine on the brains of our subjects. This study also uses a placebo, a pill that does not have any active ingredients but looks exactly like the mecamylamine and varenicline pills. We will compare the effects of giving mecamylamine or placebo to people who have schizophrenia and people who do not have schizophrenia. We know that people with schizophrenia smoke heavily and find it harder to stop smoking than most other people do. Studies have shown that people with schizophrenia may smoke more because nicotine helps their concentration and memory. We are interested in helping people with schizophrenia smoke less. Mecamylamine blocks the parts of the brain that react to nicotine and varenicline partially stimulates and partially blocks the parts of the brain that react to nicotine. Both medications may decrease the effects that smoking has on the body.
NCT00455650 ↗	Study of the Effects of Mecamylamine and Varenicline in Schizophrenia	Completed	Massachusetts General Hospital	N/A	2007-03-01	We are conducting this study to find out if blocking or partially stimulating the effects of nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug found in tobacco products. Our subjects will be people with and without mental illness (schizophrenia), smokers and non-smokers. We will use a medication called mecamylamine (Inversine) to block the effects of nicotine on the brains of our subjects. We will also use a medication called varenicline (Chantix) to partially increase the effects of nicotine on the brains of our subjects. This study also uses a placebo, a pill that does not have any active ingredients but looks exactly like the mecamylamine and varenicline pills. We will compare the effects of giving mecamylamine or placebo to people who have schizophrenia and people who do not have schizophrenia. We know that people with schizophrenia smoke heavily and find it harder to stop smoking than most other people do. Studies have shown that people with schizophrenia may smoke more because nicotine helps their concentration and memory. We are interested in helping people with schizophrenia smoke less. Mecamylamine blocks the parts of the brain that react to nicotine and varenicline partially stimulates and partially blocks the parts of the brain that react to nicotine. Both medications may decrease the effects that smoking has on the body.

Clinical Trial Conditions for INVERSINE

Condition Name

Condition Name for INVERSINE
Intervention	Trials
Cognition in Schizophrenia	1
Depression	1
Depressive Disorder	1
Major Depressive Disorder	1

Condition MeSH

Condition MeSH for INVERSINE
Intervention	Trials
Depressive Disorder	3
Depression	3
Depressive Disorder, Major	2
Disease	2

Clinical Trial Locations for INVERSINE

Trials by Country

Trials by Country for INVERSINE
Location	Trials
United States	5

Trials by US State

Trials by US State for INVERSINE
Location	Trials
Connecticut	2
Ohio	1
Massachusetts	1
Tennessee	1

Clinical Trial Progress for INVERSINE

Clinical Trial Phase

Clinical Trial Phase for INVERSINE
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	2
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for INVERSINE
Clinical Trial Phase	Trials
Completed	5
Active, not recruiting	1

Clinical Trial Sponsors for INVERSINE

Sponsor Name

Sponsor Name for INVERSINE
Sponsor	Trials
National Alliance for Research on Schizophrenia and Depression	2
Yale University	2
The Bowman Family Foundation	1

Sponsor Type

Sponsor Type for INVERSINE
Sponsor	Trials
Other	10
Industry	1
NIH	1